


PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference UPN-02811PCT		FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US03/11494	International filing date (day/month/year) 28 April 2003 (28.04.2003)	Priority date (day/month/year) 30 April 2002 (30.04.2002)	
International Patent Classification (IPC) or national classification and IPC IPC(7): A61K39/52; C12N 21/00, 21/02, 15/83, 15/86, 15/867 and US Cl.: 424/184.1, 192, 199, 204.1, 205; 435/69.1, 91.1, 91.4, 91.42, 320.1			
Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA			
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of <u>4</u> sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of ___ sheets.</p> <p>3. This report contains indications relating to the following items:</p> <p>I <input checked="" type="checkbox"/> Basis of the report</p> <p>II <input type="checkbox"/> Priority</p> <p>III <input checked="" type="checkbox"/> Non-establishment of report with regard to novelty, inventive step and industrial applicability</p> <p>IV <input type="checkbox"/> Lack of unity of invention</p> <p>V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</p> <p>VI <input type="checkbox"/> Certain documents cited</p> <p>VII <input type="checkbox"/> Certain defects in the international application</p> <p>VIII <input type="checkbox"/> Certain observations on the international application</p>			
Date of submission of the demand 14 November 2003 (14.11.2003)		Date of completion of this report 15 September 2004 (15.09.2004)	
Name and mailing address of the IPEA/US Mail Stop PCT, Attn: IPEA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230		Authorized officer  Bao Qu Li Telephone No. 571-272-1600	

Form PCT/IPEA/409 (cover sheet)(July 1998)

BEST AVAILABLE COPY

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US03/1

I. Basis of the report

1. With regard to the elements of the international application:*

- ☒ the international application as originally filed.
- ☒ the description:
pages 1-66 as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____.
- ☒ the claims:
pages 67-74 as originally filed
pages NONE, as amended (together with any statement) under Article 19
pages NONE, filed with the demand
pages NONE, filed with the letter of _____.
- ☒ the drawings:
pages 1-3 as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____.
- ☒ the sequence listing part of the description:
pages 1-29 as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____.

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in printed form.
- ☒ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages NONE
- ☐ the claims, Nos. NONE
- ☐ the drawings, sheets/fig NONE

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International Application No.

PCT/US03/

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The question whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been and will not be examined in respect of:

- ☐ the entire international application,
- ☒ claims Nos. 7-16 and 18-48

because:

- ☐ the said international application, or the said claim Nos. _____ relate to the following subject matter which does not require international preliminary examination (*specify*):

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. _____ are so unclear that no meaningful opinion could be formed (*specify*):

- ☐ the claims, or said claims Nos. _____ are so inadequately supported by the description that no meaningful opinion could be formed.

- ☒ no international search report has been established for said claims Nos. 7-16 and 18-48

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

- ☐ the written form has not been furnished or does not comply with the standard.
- ☐ the computer readable form has not been furnished or does not comply with the standard.

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. STATEMENT**

Novelty (N)	Claims <u>3-6 and 17</u>	YES
	Claims <u>1-2</u>	NO
Inventive Step (IS)	Claims <u>3-6 and 17</u>	YES
	Claims <u>1-2</u>	NO
Industrial Applicability (IA)	Claims <u>1-6 and 17</u>	YES
	Claims <u>NONE</u>	NO

2. CITATIONS AND EXPLANATIONS

Claims 1-2 are directed to a chimera ebola envelope protein comprising a functional ebola glycoprotein domain and a heterologous protein. The document of Mackenzie et al. published prior to international filing date but later than the priority date claimed teaches a plasmid encoding the Mokola and Ebola envelope proteins and a helper packaging construct of a CMV sequence (See last paragraph of page 356). Therefore, claims 1-2 are being examined in light of the international filing date.

Claims 1-2 lack novelty under PCT Article 33(2) as being anticipated by Kobinger et al. (Nature Biotechnology, March 2001, Vol. 19, pages 225-230).

Kobinger et al. Teach n EbolaZ-pseudotyped vector, which comprises the Ebola envelope protein fused with a heterologous sequence of β -gal (see page 229). Therefore, the reference of Kobinger et al. meets the limitation of claims 1-2.

Claims 1-2 lack novelty under PCT Article 33(2) as being anticipated by Mackenzie et al. (Molecule Therapy, September 2002, Vol. 6, No. 3, pages 349-358).

Mackenzie et al. teaches a plasmid encoding the Mokola and Ebola envelope proteins and a helper-packaging construct of CMV sequence (see last paragraph of page 356). Therefore, the reference of Mackenzie et al. meets the limitation of claims 1-2.

Claims 3-6 and 17 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest that a heterologous sequence fused with the binding domain of the wild-type Ebola is a non-contiguous sequence.

Claims 1-6 and 17 meet the criteria set out in PCT Article 33(4), and thus the claimed vector of Ebola has industrial applicability because the subject matter claimed can be made or used in industry.